Pulmonary melioidosis duration as per Darwin
Use a minimum of 3–4 weeks of intravenous (IV) intensive therapy for pulmonary melioidosis when pneumonia is the primary focus, with duration determined by lobar extent and presence of bacteraemia, followed by oral eradication therapy (typically trimethoprim–sulfamethoxazole) to complete 3–6 months total treatment, per the revised Darwin guideline. 1
IV intensive phase (Darwin 2020 revision; highest-quality, most recent directly applicable source):
Rationale and outcomes:
- The Darwin program (1150+ patients over decades) reports low recrudescence, relapse, and mortality with prolonged IV therapy for pulmonary foci; clinicians frequently exceeded the older 2-week minimum due to higher risk in multilobar disease and/or bacteraemia, prompting the 2020 update to 3–4 weeks IV in these phenotypes to reduce relapse and death (morbidity/mortality/QOL prioritized). 1
Eradication phase:
- After IV completion, continue oral eradication (e.g., trimethoprim–sulfamethoxazole) to reach a total course of 3–6 months; longer courses are favored when risk of relapse is high (deep foci, severe pulmonary disease), aligning with Darwin practice patterns that achieved low recurrence. 1
Pitfalls and caveats:
- Do not truncate IV therapy at 2 weeks in multilobar disease or when bacteraemic; this increases recrudescence/relapse risk. 1
- Search for and manage occult deep foci (e.g., osteomyelitis), which drove failures in Darwin data; persistent source mandates longer/intensified therapy. 1
- General HAP/VAP duration guidance is not applicable to melioidosis and should be ignored for this question. 2